Navidea Biopharmaceuticals (NYSE:NAVB) said today that it inked a definitive asset purchase agreement with Cardinal Health (NYSE:CAH) for Navidea’s Lymphoseek product.
Dublin, Ohio-based Navidea said that it will receive $80 million at closing for it’s lymphatic mapping and lymph node biopsy product, plus the opportunity for $230 million in milestone payments through 2026. More than $20 million of that amount is guaranteed over the next 3 years.
Get the full story at our sister site, Drug Delivery Business News.
The post Navidea deals NA Lymphoseek rights to Cardinal Health in $310m deal appeared first on MassDevice.
from MassDevice http://ift.tt/2ftB3NY
Cap comentari:
Publica un comentari a l'entrada